Amarin Corp Plcuk (AMRN) Change in Accured Expenses (2010 - 2026)

Amarin Corp Plcuk (AMRN) reported Change in Accured Expenses of -$14.8 million for Q1 2026, up 15.54% year-over-year from -$12.8 million in Q1 2025, and down 221.18% quarter-over-quarter from $12.2 million in Q4 2025.

Amarin Corp Plcuk (AMRN) Change in Accured Expenses (2010 - 2026) Analysis & Trends

Amarin Corp Plcuk (AMRN) has 17 years of Change in Accured Expenses data on file, last reported at -$14.8 million in Q1 2026.

  • Change in Accured Expenses for Q1 2026 came in at -$14.8 million, up 15.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.2 million (up 128.9% YoY), and the FY2025 annual result was $14.5 million, up 118.85% from the prior year.
  • Change in Accured Expenses eased to -$14.8 million in Q1 2026 per AMRN's latest filing, from $12.2 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $61.0 million in Q2 2022 and troughed at -$69.7 million in Q1 2022.
  • A 5-year average of -$10.6 million and a median of -$14.8 million in 2026 frame the typical range for Change in Accured Expenses.
  • The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses tumbled 1175.14% in 2022, then surged 176.85% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$28.1 million in 2022, then soared by 73.09% to -$7.6 million in 2023, then sank by 186.16% to -$21.6 million in 2024, then soared by 156.59% to $12.2 million in 2025, then tumbled by 221.18% to -$14.8 million in 2026.
  • Business Quant data shows AMRN's Change in Accured Expenses at -$14.8 million in Q1 2026, $12.2 million in Q4 2025, and -$3.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn -
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -629.00 Mn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn -1.59 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -75.00 Mn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn -702.00 Mn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -3.50 Bn
10 Amarin Corp Plcuk 6.77 Bn 6.59 Bn 17.77 Mn -14.82 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -14.82 Mn
Mar 31, 2026 -14.82 Mn
Dec 31, 2025 12.23 Mn
Dec 31, 2025 12.23 Mn
Sep 30, 2025 -3.71 Mn
Sep 30, 2025 -3.71 Mn
Jun 30, 2025 23.54 Mn
Jun 30, 2025 23.54 Mn
Mar 31, 2025 -17.54 Mn
Mar 31, 2025 -17.54 Mn
Dec 31, 2024 -21.61 Mn
Dec 31, 2024 -21.61 Mn
Sep 30, 2024 -28.99 Mn
Sep 30, 2024 -28.99 Mn
Jun 30, 2024 8.50 Mn
Jun 30, 2024 8.50 Mn
Mar 31, 2024 -34.90 Mn
Mar 31, 2024 -34.90 Mn
Dec 31, 2023 -7.55 Mn
Dec 31, 2023 -7.55 Mn